Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type ...(th for individuals and progress in medic...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
Date:11/6/2007
th for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.
ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.
'/>"/>
| SOURCE Takeda Pharmaceuticals North America, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...sults from chronically infected Hepatitis C,patien...ned earlier in 2008, - Study is the first to sho... antiviral effect of therapeutic Hepatitis C vacci... move into a second generation, vaccine formulate... TLR activation, VI...
(Date:9/3/2008)...NEVA, Sept. 3 /- Artelis SA and,Selex... monoclonal antibody,production with the achieveme...ter. This record level was accomplished by applyin...erformance stable Selexis CHO,production cell line...at,Selexis SA using their proprietary Selexis Gene...
(Date:9/3/2008)...Multaq(R) (dronedarone) decreased the risk of,stro...trial flutter already adequately trea... Sept. 3 /- The results of ...udy were presented today at,the clinical trial upd...congress 2008, in Munich, Germany. Previous result...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 1Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 2Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 1Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 2Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 1Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 1HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 3[0] Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study[0] Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program[0] Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter[0] Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
... Demonstrated Among Patients with,Active Disease, ...-,ChemoCentryx, Inc., a clinical-stage biopharmace...and commercializing,orally-administered therapeuti...a today from the company,s Phase 2 clinical trial ...nflammatory agent,that targets the chemokine recep...
...Generex Biotechnology Corporation,(NasdaqCM:GNBT) ...of Immunobiology at its wholly-owned Antigen Expre...elopment strategy at an,international conference i...ng New Anti-Infective Agents - Challenges and,Oppo...nti-infectives-forum.com">www.anti-infectives-foru...
Other Medicine Technology:ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5Generex Biotechnology Vaccine Strategy Presented at International,Conference in London 2Generex Biotechnology Vaccine Strategy Presented at International,Conference in London 3(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2...tem reserachers have identified a key receptor tha...e treatment of acute respiratory distress syndrome... a life-threatening condition. The receptor is s...ht, smell and taste (G-protein coupled receptors) ...
...doss urged the Prime Minister Mr. Man Mohan Singh ... smoking in the films and television. // With the ...ing failing to reach consensus on modalities for i...ss, the minister approached Prime Minister Manmoha...
...rchers might be able to isolates molecule that wou...ory.// The revolutionary study has been done indep...Children's Hospital Boston and they have identifie... how neurons change as a result of individual expe...
...he Bihar government on Wednesday for neglecting th...hief Minister of Bihar Mr. Nitish Kumar gave the n...which was carried out with immediate effect. Last...issed three medical officers and initiated departm...
Other Medicine News:PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts.
Velocity works cooperatively with LabSofts LabNet LIS, allowing the convenience of 24-hour access to information from satellite lab locations, hospitals, physician offices and even homes.
...eld (130" x 85") allows the surgeon to view the pa...hile remaining in the sterile field. , ,Electroca...ling cords while maintaining longer cord length st...large particle screen accommodates the larger inci...
The Bohn™ Extremity Drape is economically sound - this single extremity drape replaces two large antimicrobial impregnated "Vi-Drapes" ...the traditional "shower curtain"...and your current "ex
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |